Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24517557 | 0.85 | KDM4C (0.54) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17288096 | 0.84 | MEN1 (0.51) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL15732998 | 0.84 | MEN1 (0.51) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL29703952 | 0.82 | KDM4C (0.54) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17288212 | 0.82 | KDM4C (0.53) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL30225190 | 0.81 | KDM4C (0.49) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL23975779 | 0.81 | KDM4C (0.49) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL30225192 | 0.81 | KDM4C (0.49) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18106022 | 0.80 | KDM4C (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17323672 | 0.79 | KMT2A (0.57) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | MEN1 3828/4885KMT2A 1587/4885KDM4C 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.